Jury Says Johnson & Johnson Must Pay $8-Billion in a Blow-Out Verdict Over Male Breast Growth Linked to the Drug, Risperdal

Wiki
image_pdfimage_print
A Philadelphia jury awarded a plaintiff, Nicholas Murray, $8-billion in punitive fines that were leveled against Johnson & Johnson, the manufacturer of anti-psychotic drug, Risperidal, after he claimed that the the drug company failed to warn that young men could grow enlarged breasts from using the product. Murray, now 26, alleged that he developed breasts after his doctors began prescribing him Risperdal off-label in 2003 after a psychologist diagnosed him with autism spectrum disorder. Doctors are allowed to prescribe medicines as they see fit, while companies are only allowed to promote their drugs for approved uses. There are thousands more Risperdal cases pending in the state. It is likely that the award will be reduced on appeal. -GEG

(Reuters) – Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.

The Philadelphia Court of Common Pleas jury’s verdict in favor of Nicholas Murray came in the first case in which a Pennsylvania jury had been able to consider awarding punitive damages in one of thousands of Risperdal cases pending in the state.

“This jury, as have other juries in other litigations, once again imposed punitive damages on a corporation that valued profits over safety and profits over patients,” Murray’s lawyers, Tom Kline and Jason Itkin, said in a joint statement. “Johnson & Johnson and (subsidiary) Janssen chose billions over children.”

J&J said the award was “grossly disproportionate with the initial compensatory award in this case, and the company is confident it will be overturned.” It added that the jury in the case had not been allowed to hear evidence of Risperdal’s benefits.

Professor Carl Tobias of the University of Richmond School of Law said he expects the punitive damages to be lowered on appeal, citing a U.S. Supreme Court decision which found that “few awards exceeding a single-digit ratio between punitive and compensatory damages, to a significant degree, will satisfy due process.”

Tobias said the verdict was about sending a message.

 

“A jury, if it’s outrageous enough conduct, will award a big number and let the lawyers and judges work it out,” he said.

Tobias added that the verdict could be a sign that J&J will face more large damages awards in other Risperdal cases.

“The kind of evidence in this trial may persuade another jury or judge to do something similar,” he said.

Murray, like other male plaintiffs in the mass tort litigation over Risperdal, alleges that he developed breasts after being prescribed the medicine when he was a minor. The U.S. Food and Drug Administration approved the drug in late 1993 for treating schizophrenia and episodes of bipolar mania in adults.

Plaintiffs claim that J&J failed to warn of the risk of gynecomastia, the development of enlarged breasts in males, associated with Risperdal, which they say the company marketed for unapproved uses with children.


Read full article here…

Visit our Classified ads.

Check out our Classified ads at the bottom of this page.

Recent stories & commentary

Health

Is COVID-19 Being Blamed for 5G Radiation Sickness?

November 30, 2020 Edward Hendrie 4

Dr. Magda Havas, Ph.D, performed a study comparing the average number of cases, deaths, and tests for Covid-19 in states with and without 5G. She reported that Covid cases are 95% higher and Covid deaths 126% higher in states with 5G than in states without 5G.

GEG Commentary

Mixed Emotions Over Continued School Shutdowns

November 27, 2020 Tammy Bruce 1

Continued shutdowns of schools across the US have caused an alarming decline in learning. Remote virtual learning on computers is not working. Teachers’ unions have lobbied to keep schools closed. Public schools have a radicalizing influence. Homeschooling is on the rise, and that may be the ultimate solution.

Classifieds

For classified advertising rates and terms, click here. The appearance of ads on this site does not signify endorsement by the publisher. We do not attempt to verify the accuracy of statements made therein or vouch for the integrity of advertisers. However, we will investigate complaints from readers and remove any message we find to be misleading or that promotes anything fraudulent, illegal, or unethical.

Subscribe
Notify of
guest
2 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
trackback
Jury Says Johnson & Johnson Must Pay $8-Billion in a Blow-Out Verdict Over Male Breast Growth Linked to the Drug, Risperdal | WeAreChangeTV.US
1 year ago

[…] 10, 2019 Reuters No Comments This post was originally published on this […]

trackback
Jury Says Johnson & Johnson Must Pay $8-Billion in a Blow-Out Verdict Over Male Breast Growth Linked to the Drug, Risperdal
1 year ago

[…] Posted October 18, 2019 Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.  Read more. […]